PMID- 32249420
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20201026
IS  - 1600-0404 (Electronic)
IS  - 0001-6314 (Linking)
VI  - 142
IP  - 2
DP  - 2020 Aug
TI  - The evidence for switching dibenzazepines in people with epilepsy.
PG  - 121-130
LID - 10.1111/ane.13248 [doi]
AB  - The dibenzazepines particularly carbamazepine are associated with known adverse 
      effects (AEs) and drug to drug interactions. Eslicarbazepine acetate (ESL) is 
      structurally distinct from other members of the dibenzazepine family and has the 
      advantage of once daily dosing. Observational and trial data report successful 
      switching from older dibenzazepines to ESL. The evidence base for doing so is 
      unclear and not standardized. This is a literature review following the PRISMA 
      scoping guidelines identifying the evidence of switching dibenzazepines. 
      Transition methods, ratios, tolerance to change, adverse effects and retention 
      post-change were evaluated. Study quality was assessed using the Oxford Centre 
      for Evidence Based Medicine levels of evidence. Seven studies investigated the 
      outcome of transition between carbamazepine and or oxcarbazepine to ESL, with 
      specific data on the transition dose ratio and scheduling. The available data 
      suggest that the overnight transition between oxcarbazepine and ESL in a 1:1 
      ratio (most common) is generally well tolerated with high retention rates. The 
      transition showed improvement in adverse events associated with oxcarbazepine 
      across a variety of domains. Almost 60% transitioned because of adverse events 
      experienced no further symptoms at 12 months. There is less data on the 
      transition from carbamazepine to ESL. The evidence available suggests an 
      overnight transition in the ratio of 1:1.3-1.5. The retention rate following 
      transition from carbamazepine to ESL was 69% (follow-up of 4 months) with almost 
      half of those transitioned because of adverse events experiencing no further 
      symptoms. There is Grade C evidence available to help guide clinicians in the 
      transition.
CI  - (c) 2020 The Authors. Acta Neurologica Scandinavica published by John Wiley & Sons 
      Ltd.
FAU - Watkins, Lance
AU  - Watkins L
AD  - Swansea Bay University Health Board, Swansea, UK.
FAU - O'Dwyer, Marie
AU  - O'Dwyer M
AD  - School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin, Ireland.
FAU - Oak, Katy
AU  - Oak K
AD  - Royal Cornwall Hospital Trust, Truro, UK.
FAU - Lawthom, Charlotte
AU  - Lawthom C
AD  - Aneurin Bevan University Health Board, Newport, UK.
AD  - Swansea University, Swansea, UK.
FAU - Maguire, Melissa
AU  - Maguire M
AD  - Leeds General Infirmary, Leeds, UK.
AD  - Leeds Institute of Biomedical & Clinical Sciences, University of Leeds, Leeds, 
      UK.
FAU - Thomas, Rhys
AU  - Thomas R
AD  - Institute of Neuroscience, Newcastle University, Newcastle-upon-Tyne, UK.
AD  - Royal Victoria Infirmary, Newcastle-upon-Tyne, UK.
FAU - Shankar, Rohit
AU  - Shankar R
AUID- ORCID: 0000-0002-1183-6933
AD  - Cornwall Partnership NHS Foundation Trust, Threemilestone Industrial Estate, 
      Truro, UK.
AD  - University of Exeter Medical School, Knowledge Spa, Truro, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200427
PL  - Denmark
TA  - Acta Neurol Scand
JT  - Acta neurologica Scandinavica
JID - 0370336
RN  - 0 (Anticonvulsants)
RN  - 0 (Dibenzazepines)
RN  - 33CM23913M (Carbamazepine)
RN  - BEA68ZVB2K (eslicarbazepine acetate)
SB  - IM
MH  - Anticonvulsants/adverse effects/*therapeutic use
MH  - Carbamazepine/adverse effects/*therapeutic use
MH  - Dibenzazepines/adverse effects/*therapeutic use
MH  - Drug Substitution/*methods/trends
MH  - Epilepsy/diagnosis/*drug therapy
MH  - Evidence-Based Medicine/*methods/trends
MH  - Humans
OTO - NOTNLM
OT  - efficacy
OT  - epilepsy
OT  - eslicarbazepine acetate
OT  - safety
OT  - switch
OT  - tolerability
EDAT- 2020/04/07 06:00
MHDA- 2020/10/27 06:00
CRDT- 2020/04/07 06:00
PHST- 2020/03/01 00:00 [received]
PHST- 2020/03/21 00:00 [revised]
PHST- 2020/03/27 00:00 [accepted]
PHST- 2020/04/07 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
PHST- 2020/04/07 06:00 [entrez]
AID - 10.1111/ane.13248 [doi]
PST - ppublish
SO  - Acta Neurol Scand. 2020 Aug;142(2):121-130. doi: 10.1111/ane.13248. Epub 2020 Apr 
      27.